Issues with reporting and interpretation of Khan et al. 2021

Nicholas J DeVito; Henry Drysdale

doi:10.1186/s12879-022-07551-8

Issues with reporting and interpretation of Khan et al. 2021

BMC Infect Dis. 2022 Jun 22;22(1):567. doi: 10.1186/s12879-022-07551-8.

Authors

Nicholas J DeVito¹, Henry Drysdale²

Affiliations

¹ Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, England. nicholas.devito@phc.ox.ac.uk.
² Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, England.

Abstract

A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading.

Keywords: Convalescent Plasma; Covid-19; Trial Registration; Trial Reporting; Trials Transparency.

Publication types

Letter

MeSH terms

COVID-19 Serotherapy
COVID-19* / therapy
Humans
Immunization, Passive